69 related articles for article (PubMed ID: 9102151)
41. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
42. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
43. Alzheimer's disease. The density of amygdalar neuritic plaques is associated with the severity of neurofibrillary pathology and the degree of beta-amyloid protein deposition in the cerebral cortex.
Yilmazer-Hanke DM
Acta Anat (Basel); 1998; 162(1):46-55. PubMed ID: 9789108
[TBL] [Abstract][Full Text] [Related]
44. [Alzheimer's disease lesions: from morphology to cell biology].
Hauw JJ; Seilhean D; Piette F; Uchihara T; Duyckaerts C
Bull Acad Natl Med; 1996 Oct; 180(7):1687-700; discussion 1700-1. PubMed ID: 9102151
[TBL] [Abstract][Full Text] [Related]
45. [Alzheimer's disease: lesions and their progression].
Duyckaerts C; Colle MA; Delatour B; Hauw JJ
Rev Neurol (Paris); 1999; 155 Suppl 4():S17-27. PubMed ID: 10637934
[TBL] [Abstract][Full Text] [Related]
46. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
47. Cholesterol and pathological processes in Alzheimer's disease.
Yanagisawa K
J Neurosci Res; 2002 Nov; 70(3):361-6. PubMed ID: 12391598
[TBL] [Abstract][Full Text] [Related]
48. Plaques, tangles, and memory loss in mouse models of neurodegeneration.
Eriksen JL; Janus CG
Behav Genet; 2007 Jan; 37(1):79-100. PubMed ID: 17072762
[TBL] [Abstract][Full Text] [Related]
49. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
50. Variations in the neuropathology of familial Alzheimer's disease.
Shepherd C; McCann H; Halliday GM
Acta Neuropathol; 2009 Jul; 118(1):37-52. PubMed ID: 19306098
[TBL] [Abstract][Full Text] [Related]
51. [Pathogenesis of Alzheimer's disease].
Alegre M; Noé E; Luquin MR
Rev Med Univ Navarra; 1997; 41(1):46-57. PubMed ID: 9527714
[TBL] [Abstract][Full Text] [Related]
52. A decade of modeling Alzheimer's disease in transgenic mice.
McGowan E; Eriksen J; Hutton M
Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
[TBL] [Abstract][Full Text] [Related]
53. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
Crouch PJ; White AR; Bush AI
FEBS J; 2007 Aug; 274(15):3775-83. PubMed ID: 17617225
[TBL] [Abstract][Full Text] [Related]
54. [Morphologic and molecular neuropathology of Alzheimer's disease].
Duyckaerts C; Panchal M; Delatour B; Potier MC
Ann Pharm Fr; 2009 Mar; 67(2):127-35. PubMed ID: 19298896
[TBL] [Abstract][Full Text] [Related]
55. The involvement of the ubiquitin system in Alzheimer's disease (review).
Pallares-Trujillo J; Lopez-Soriano FJ; Argilés JM
Int J Mol Med; 1998 Jul; 2(1):3-15. PubMed ID: 9854137
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
